|
Video: What is a Stock Split?
|
|
Hepion Pharmaceuticals is a biopharmaceutical company focused primarily on the development of drug therapy for treatment of chronic fibrosis related diseases. The main therapeutic approach specifically targets the disease mechanism related to fibrosis as well as, inflammation and shows potential for the treatment of non-alcoholic steatohepatitis, hepatocellular carcinoma, viral hepatitis, and other fibrotic diseases. Co.'s cyclophilin inhibitor, rencofilstat, is being developed to address multiple pathologies related to advanced fibrotic diseases. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of fibrosis. According to our HEPA split history records, Hepion Pharmaceuticals has had 1 split. | |
|
Hepion Pharmaceuticals (HEPA) has 1 split in our HEPA split history database. The split for HEPA took place on May 11, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of HEPA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Hepion Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the HEPA split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Hepion Pharmaceuticals shares, starting with a $10,000 purchase of HEPA, presented on a split-history-adjusted basis factoring in the complete HEPA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/05/2014 |
|
End date: |
05/01/2024 |
|
Start price/share: |
$41.00 |
|
End price/share: |
$1.36 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-96.68% |
|
Average Annual Total Return: |
-28.87% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$331.84 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
05/11/2023 | 1 for 20 |
|
|